Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Pfizer
Study ID
NCT00037804
Phase
PHASE1
Status
Completed

Conditions

  • Chemotherapy
  • Liver Dysfunction
  • Neoplasms, Solid Tumor
  • Unspecified Adult Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.

Key Dates

First listed
May 22, 2002
Status verified
Aug 2009

Study Design

Primary purpose
TREATMENT

Locations (4)

FacilityCityStateZIPSite coordinators
Research CenterDetroitMichigan48201-
Research CenterNew BrunswickNew Jersey08901-
Research CenterNashvilleTennessee37232-
Research CenterMarshfieldWisconsin54449-

Find similar trials in Detroit, MI

By research site
Research Center· Detroit, MIResearch Center· New Brunswick, NJResearch Center· Nashville, TNResearch Center· Marshfield, WI

Related Studies